 |
Photo = Yuhan |
[Alpha Biz= Reporter Kim Jisun] On the 21st, NH Investment & Securities announced that Yuhan Corporation's LECLAZA, a lung cancer treatment, received approval from the U.S. Food and Drug Administration (FDA), maintaining its target price at 100,000 won. The previous closing price for Yuhan Corporation was 94,000 won.
In their report, NH Investment & Securities stated, "This is a symbolic event that enhances confidence in domestic biotech exports," and analyzed that the global market size for lung cancer treatments is currently $7 billion, with AstraZeneca's product, Tagrisso, dominating with $5.8 billion.
The firm estimated that LECLAZA's performance would reflect 60% of Tagrisso's revenue for first-line treatments and 15% for second-line treatments. They noted that survival data and formulation changes to be disclosed in the future will be key points for determining market share.
NH Investment & Securities has maintained its "Buy" recommendation for Yuhan Corporation.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
